Ray-Coquard Isabelle, Bachelot Thomas, Saba Chadi, Confavreux Cyrille, Brantus Jean-François, Rustam Fadi, Ghesquière Hervé, Sebban Catherine, Biron Pierre, Guastalla Jean-Paul, Blay Jean-Yves
Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon.
Bull Cancer. 2007 Jul;94 Spec No:S191-6.
After over 30 years of theorizing, the use of angiogenesis inhibitors as anticancer therapy has finally moved from the realm of research to reality. Normal adult vasculature is generally quiescent in nature, with endothelial cells dividing approximately every 10 years. In contrast, the growth of tumours requires constant vascular growth and remodelling in order for solid tumours to grow beyond 1-2 mm3 in size. Vascular endothelial growth factor (VEGF) and its receptors are key regulators of the process of angiogenesis, which make them attractive therapeutic targets. A multitude of VEGF-targeted inhibitory agents are currently being investigated for the treatment of cancer. This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers.
经过30多年的理论研究，血管生成抑制剂作为抗癌疗法终于从研究领域走向了临床应用。正常成年血管系统通常处于静止状态，内皮细胞大约每10年分裂一次。相比之下，肿瘤的生长需要持续的血管生成和重塑，以便实体瘤生长超过1-2立方毫米。血管内皮生长因子（VEGF）及其受体是血管生成过程的关键调节因子，这使其成为有吸引力的治疗靶点。目前正在研究多种针对VEGF的抑制剂用于癌症治疗。这篇综述文章重点关注血管生成抑制剂在乳腺癌、肺癌和结直肠癌治疗中的最新进展。
